Precision System Science Co., Ltd.
PCNEF
Other OTC2.28
USD
- -
- -
ISIN
JP3833400009
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-43.56
76.60
5Y
-43.56
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Yu Sugiyama
- Full Time Employees
- 158
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 88 Kamihongou Matsudo Japan 271-0064
- IPO Date
- Aug 29, 2022
- Website
- pss.co.jp
- Similar Companies
- Business
- Precision System Science Co., Ltd. develops, manufactures, and distributes automated systems and instruments primarily for genetic and protein analysis as well as in vitro diagnostics. Its core products include nucleic acid extraction systems such as the magLEAD series (including magLEAD 5bL and discontinued magLEAD 12gC), and the fully automated molecular diagnostics geneLEAD series including geneLEAD XII plus and geneLEAD VIII, which cover processes from nucleic acid extraction to real-time PCR analysis. The company also supplies plastic consumables, reagents for nucleic acid extraction and biochemical testing, and research-focused instruments such as the LecChip series. Precision System Science utilizes proprietary Magtration technology, a recognized standard for automated nucleic acid extraction, integrated in its automated real-time PCR systems. The company operates primarily in Japan and serves global markets with its CE-IVD certified products. Founded in 2002 and headquartered in Chiba, Japan, Precision System Science continues to advance solutions for gene and protein analysis. Recent major developments include the company’s strategic 5-year OEM product supply agreement with ELITechGroup initiated in 2024, enhancing its molecular diagnostics market presence. In 2024, Precision System Science divested Universal Bio Research Co., Ltd. through a sale valued at approximately ¥60 million, signaling a refinement of its business portfolio. It also launched joint sales efforts for its geneLEAD XXIV and magLEAD 4gC and 12gC LiNK systems to expand product reach. The company maintains close collaborations, including a distribution agreement with DiagCor Life Science Ltd., and continues to emphasize growth in automated molecular testing platforms and sample-to-result instrumentation. These actions reflect Precision System Science's ongoing commitment to advancing automated gene and protein analytical solutions in the healthcare and life sciences sectors.